US · NRIX · BIOTECHNOLOGY
Nurix Therapeutics, Inc. (NRIX) intrinsic value and stock valuation
$12.85as of 2026-11-21 · Mkt cap 2.61B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Nurix Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values NRIX with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from NRIX’s statements →
Nurix Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Tango Therapeutics, Inc. (TNGX) $21.73
- Kodiak Sciences Inc. (KOD) $97.17
- UroGen Pharma Ltd. (URGN) $27.65
- Fortrea Holdings Inc. (FTRE) $18.55
- Septerna Inc (SEPN) $38.61
- Xencor, Inc. (XNCR) $33.26
- EyePoint Pharmaceuticals, Inc. (EYPT) $0.23
- Kura Oncology, Inc. (KURA) $6.91
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $84M | $54.6M | $77M | $38.6M | $29.8M |
| Operating income | -$-285.67M | -$-213.03M | -$-155.06M | -$-183.87M | -$-117.89M |
| Net income | -$-264.46M | -$-193.57M | -$-143.95M | -$-180.36M | -$-117.19M |
| EPSd | -$-3.05M | -$-2.88M | -$-2.65M | -$-3.71M | -$-2.73M |
| Operating cash flow | -$-249.47M | -$-172.58M | -$-81.36M | -$-159.81M | -$-84.36M |
| Capital expenditure | -$-14M | -$-9.27M | -$-8.4M | -$-12.24M | -$-5.66M |
| Free cash flow | -$-263.47M | -$-181.86M | -$-89.77M | -$-172.05M | -$-90.03M |
| Total assets | $688.1M | $669.3M | $355.6M | $416.8M | $476.8M |
| Total debt | $55.7M | $28.3M | $30.6M | $12M | $13M |
| Net debt | -$-191.23M | -$-81.69M | -$-24.01M | -$-52.51M | -$-67.47M |
| Total equity | $538.8M | $527M | $200.5M | $303.7M | $342.3M |
| Cash and short-term investments | $592.9M | $609.6M | $287.9M | $309.1M | $295.7M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $84M | $54.6M | $77M | $38.6M | $29.8M |
| Cost of revenue | $18.9M | $221.6M | $189.2M | $184.5M | $116.4M |
| Gross profit | $65.1M | -$-167.08M | -$-112.16M | -$-145.87M | -$-86.68M |
| Research and development expenses | $308.2M | $221.6M | $189.2M | $184.5M | $116.4M |
| Selling, general and administrative expenses | $52.7M | $45.9M | $42.9M | $38M | $31.2M |
| Other expenses | -$-10.12M | -$-221.63M | -$-189.15M | -$-184.5M | -$-116.43M |
| Operating expenses | $350.8M | $45.9M | $42.9M | $38M | $31.2M |
| Cost and expenses | $369.7M | $267.6M | $232.1M | $222.5M | $147.6M |
| Interest income | $22M | $19.7M | $11.1M | $3.51M | $820K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $18.9M | $8.02M | $6.13M | $4.15M | $1.99M |
| Ebitda | -$-244.84M | -$-185.28M | -$-137.81M | -$-176.21M | -$-115.07M |
| Operating income | -$-285.67M | -$-213.03M | -$-155.06M | -$-183.87M | -$-117.89M |
| Total other income/expenses, net | $22M | $19.7M | $11.1M | $3.51M | $820K |
| Income before tax | -$-263.7M | -$-193.3M | -$-143.95M | -$-180.36M | -$-117.06M |
| Income tax expense | $760K | $270K | $0.00 | $0.00 | $130K |
| Net income | -$-264.46M | -$-193.57M | -$-143.95M | -$-180.36M | -$-117.19M |
| Weighted average shares outstanding | $86.7M | $67.1M | $54.3M | $48.6M | $42.9M |
| Weighted average diluted shares outstanding | $86.7M | $67.1M | $54.3M | $48.6M | $42.9M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $592.9M | $609.6M | $287.9M | $309.1M | $295.7M |
| Net receivables | $0.00 | $1.5M | $800K | $1.1M | $6.2M |
| Inventory | $0.00 | $0.00 | $0.00 | -$-1.1M | $0.00 |
| Total current assets | $606.8M | $619.4M | $295.5M | $318.5M | $311.1M |
| Property, plant and equipment, net | $73M | $45.9M | $48M | $29.5M | $25.3M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $7.42M | $63.9M | $137.5M |
| Total non-current assets | $81.3M | $50M | $60.1M | $98.3M | $165.7M |
| Total assets | $688.1M | $669.3M | $355.6M | $416.8M | $476.8M |
| Accounts payable | $11.2M | $11.5M | $6.4M | $5.06M | $6.65M |
| Short-term debt | $2.82M | $8.01M | $7.49M | $5.53M | $3.85M |
| Deferred revenue | $17.6M | $38.4M | $48.1M | $37.6M | $41.2M |
| Total current liabilities | $86.5M | $95.9M | $87M | $70.7M | $66.3M |
| Long-term debt | $52.9M | $20.3M | $23.1M | $6.43M | $9.19M |
| Deferred revenue, non-current | $10M | $26.2M | $45M | $36M | $59M |
| Total non-current liabilities | $62.9M | $46.5M | $68.2M | $42.4M | $68.2M |
| Capital lease obligations | $55.7M | $28.3M | $23.1M | $6.43M | $9.19M |
| Total liabilities | $149.4M | $142.4M | $155.1M | $113.1M | $134.5M |
| Common stock | $100K | $80K | $50K | $50K | $40K |
| Retained earnings | -$-1B | -$-738.77M | -$-545.2M | -$-401.25M | -$-220.89M |
| Accumulated other comprehensive income (loss) | $100K | $150K | -$-660K | -$-4.32M | -$-610K |
| Total equity | $538.8M | $527M | $200.5M | $303.7M | $342.3M |
| Total investments | $346M | $499.6M | $240.7M | $308.6M | $352.4M |
| Total debt | $55.7M | $28.3M | $30.6M | $12M | $13M |
| Net debt | -$-191.23M | -$-81.69M | -$-24.01M | -$-52.51M | -$-67.47M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-264.46M | -$-193.57M | -$-143.95M | -$-180.36M | -$-117.19M |
| Depreciation and amortization | $18.9M | $16.4M | $13.7M | $10.8M | $6.08M |
| Stock-based compensation | $38M | $33.9M | $33.7M | $28.1M | $15.8M |
| Change in working capital | -$-31.6M | -$-18.4M | $20.1M | -$-19.02M | $9.11M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $6M | -$-6M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $6.77M |
| Accounts payable | -$-630K | $5.21M | $1.61M | $90K | $1.59M |
| Net cash provided by operating activities | -$-249.47M | -$-172.58M | -$-81.36M | -$-159.81M | -$-84.36M |
| Investments in property, plant and equipment | -$-14M | -$-9.27M | -$-8.4M | -$-12.24M | -$-5.66M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-39.44M | $102.6M |
| Net cash used for investing activities | $147.9M | -$-257.71M | $68.3M | $27.2M | -$-108.25M |
| Common stock issued | $238.6M | $478.5M | $3.22M | $19.4M | $150.2M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $238.6M | $485.7M | $3.22M | $117.2M | $153.9M |
| Net change in cash | $137M | $55.4M | -$-9.85M | -$-15.42M | -$-38.73M |
| Cash at end of period | $247.9M | $110.9M | $55.5M | $65.4M | $80.8M |
| Operating cash flow | -$-249.47M | -$-172.58M | -$-81.36M | -$-159.81M | -$-84.36M |
| Capital expenditure | -$-14M | -$-9.27M | -$-8.4M | -$-12.24M | -$-5.66M |
| Free cash flow | -$-263.47M | -$-181.86M | -$-89.77M | -$-172.05M | -$-90.03M |
Line items
Line items
Line items
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
- CEO
- Arthur T. Sands
- Employees
- 317
- Beta
- 1.80
Explore
Frequently asked questions
What is the intrinsic value of Nurix Therapeutics, Inc. (NRIX)?
Nurix Therapeutics, Inc. (NRIX) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is NRIX undervalued?
NRIX trades at a price of $12.85 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.